Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial

Suzana Margareth Lobo, Gaétan Plantefève, Girish Nair, Adilson Joaquim Cavalcante, Nara Franzin de Moraes, Estevao Nunes, Otis Barnum, Claudio Marcel Berdun Stadnik, Maria Patelli Lima, Muriel Lins, Ludhmila Abrahao Hajjar, Christopher Lipinski, Shaheen Islam, Fabiano Ramos, Tiago Simon, Jean Benoît Martinot, Thomas Guimard, Arnaud Desclaux, Bertrand Lioger, Fernando Carvalho NeuenschwanderBruno DeSouza Paolino, Alpesh Amin, Samuel Amil Acosta, Daniel Forde Dilling, Edgardo Cartagena, Brian Snyder, Edouard Devaud, Ana Karolina Barreto Berselli Marinho, Suzana Tanni, Patricia Medeiros Milhomem Beato, Stephan De Wit, Vani Selvan, Jeffrey Gray, Ricardo Fernandez, Valérie Pourcher, Lee Maddox, Richard Kay, Anait Azbekyan, Mounia Chabane, Cendrine Tourette, Luis Everton Esmeraldino, Pierre J. Dilda, René Lafont, Jean Mariani, Serge Camelo, Sandrine Rabut, Samuel Agus, Stanislas Veillet, Waly Dioh, Rob van Maanen, Capucine Morelot-Panzini

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences